‘The world of Cat TV is more cut throat than you would ever imagine’ – inside the strange business of TV… for cats
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab Business Wire Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)1. At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients. The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment. Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 Business Wire Almirall’s scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two expert-led symposia and an interactive industry AD hub session. New clinical data show consistent efficacy and effectiveness in atopic dermatitis treatment across body regions with lebrikizumab, including high-impact areas such as the face and neck1,2, while late-breaking ADlong results highlight sustained improvements in skin signs and itch with up to five years of treatment3. Final two-year data from the POSITIVE clinical study demonstrate the benefits on patient overall well-being and quality of life during tildrakizumab treatment4,5, and further data show evidence in patients with high disease burden and previous biologic treatment6,7. Almirall’s commitment to medical dermatology is reflected by its Gold Sponsorship of EADV 2026 and the launch of the ‘Face It’-campaign to raise awareness of the burden of atopic dermatitis with face and neck involvement, addressing the broader impact of skin diseases on patients.
Verdiva Bio Presents Preclinical Data on VRB-103, a Selective Oral Amylin Peptide Analog, at 62nd EASD Annual Meeting Business Wire Preclinical data demonstrated that VRB-103 has high potency and strong amylin receptor selectivity, reinforcing its differentiated profile as a selective oral amylin peptide analog VRB-103 is currently in Phase 1 clinical development, with initial data as a monotherapy and in combination with VRB-101, anticipated by the end of 2026
MultiBank Group Secures Two Awards at Forex Expo Dubai 2026 September 25, 2026 The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact
Finimize’s Modern Investor Summit Returns to London This October September 24, 2026 Bill Ackman headlines alongside leading voices from Aberdeen Investments, Charles Schwab, FTSE Russell, L&G and more
Lattice to Showcase Next Gen Automotive Sensing Innovations at AutoSens Europe 2026 September 14, 2026 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming AutoSens Europe 2026, taking place on Sept. 22 – 24, 2026, in Barcelona, Spain. As part of the event, Lattice will deliver a technical presentation and host a demo showcase focused on how its low [...]
Everbridge Introduces Everbridge 360 AI, the Next Evolution of High Velocity Critical Event Management September 14, 2026 Enhanced platform combines proven resilience workflows with embedded AI and enterprise-grade governance to help organizations make better decisions, respond faster, and continuously strengthen operational resilience
KONGSBERG Selects Echodyne MESA Radar for Counter-UAS Weapon Systems September 9, 2026 Low-SWaP, precision-tracking radar integrated with PROTECTOR RS4 and RS6 remote weapon stations to strengthen detection-to-defeat performance against drones
Orange Logic Brings NVIDIA Nemotron to Agent Studio, Advancing Governed AI Agents for Enterprise Content September 8, 2026 Orange Logic Agent Studio enables enterprises to build AI agents that understand content, reason across business context, and take action within governed workflows, powered by NVIDIA Nemotron open models
Aqara Showcases The New Smart Lighting Series and Immersive Smart Home Experience at IFA 2026 September 4, 2026 Aqara, a global leader in IoT, today announced a new lineup of smart lighting products and a global community platform for smart space creators, at IFA 2026 in Berlin. The announcements reflect Aqara’s ongoing vision for AI-driven spatial intelligence — spaces that understand their users and adapt to how people actually live in them. This [...]